CY1111456T1 - Συνθεσεις περιλαμβανουσες νεραμεξανη - Google Patents

Συνθεσεις περιλαμβανουσες νεραμεξανη

Info

Publication number
CY1111456T1
CY1111456T1 CY20111100444T CY111100444T CY1111456T1 CY 1111456 T1 CY1111456 T1 CY 1111456T1 CY 20111100444 T CY20111100444 T CY 20111100444T CY 111100444 T CY111100444 T CY 111100444T CY 1111456 T1 CY1111456 T1 CY 1111456T1
Authority
CY
Cyprus
Prior art keywords
compositions
neramexani
recommendations
container
inclusive
Prior art date
Application number
CY20111100444T
Other languages
English (en)
Inventor
Mahendra G Dedhiya
Shashank Mahashabde
Yan Yang
Anshu Goel
Erhard Seiller
Bernhard Hauptmeier
Original Assignee
Merz Pharma Gmbh & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34572981&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111456(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co. Kgaa filed Critical Merz Pharma Gmbh & Co. Kgaa
Publication of CY1111456T1 publication Critical patent/CY1111456T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση αναφέρεται σε συστάσεις φαρμακευτικών ενώσεων, όπως οι Κυκλοεξαμίνες και οι Αμινοαδαμαντάνες που έχουν αντιμικροβιακές ιδιότητες. Συγκεκριμένα, αναφέρεται σε συστάσεις υδατικής βάσεως με μειωμένες ποσότητες συντηρητικών που επιτρέπουν την ασφαλή και ευνοϊκή χορήγηση και την ευέλικτη δοσολόγηση και οι οποίες, στην περίπτωση των πόσιμων συστάσεων, είναι εύκολες στην κατάποση. Προαιρετικά, οι συνθέσεις περιέχουν συνιστώσες που παρέχουν την προαπαιτούμενη σταθερότητα και χρόνο αποθηκεύσεως μειώνοντας ή αποφεύγοντας την περίπηξη της συνθέσεως περί του περιβλήματος του δοχείου που οδηγεί σε διαρροές και δυσκολία στο άνοιγμα του δοχείου.
CY20111100444T 2003-11-05 2011-05-09 Συνθεσεις περιλαμβανουσες νεραμεξανη CY1111456T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51798103P 2003-11-05 2003-11-05
EP04810445A EP1684715B1 (en) 2003-11-05 2004-11-05 Compositions comprising neramexane

Publications (1)

Publication Number Publication Date
CY1111456T1 true CY1111456T1 (el) 2015-08-05

Family

ID=34572981

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100444T CY1111456T1 (el) 2003-11-05 2011-05-09 Συνθεσεις περιλαμβανουσες νεραμεξανη

Country Status (19)

Country Link
US (4) US20070270500A1 (el)
EP (2) EP2289489B1 (el)
AR (1) AR046314A1 (el)
AT (1) ATE504290T1 (el)
AU (1) AU2004287489B9 (el)
CA (1) CA2543865C (el)
CL (1) CL2008000125A1 (el)
CY (1) CY1111456T1 (el)
DE (1) DE602004032164D1 (el)
DK (1) DK1684715T3 (el)
ES (2) ES2507500T3 (el)
HR (1) HRP20110482T1 (el)
IL (1) IL175623A (el)
PL (1) PL1684715T3 (el)
PT (1) PT1684715E (el)
SI (1) SI1684715T1 (el)
TW (1) TWI350750B (el)
WO (1) WO2005044228A2 (el)
ZA (1) ZA200603561B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
CN101389315A (zh) * 2004-06-17 2009-03-18 莫茨药物股份两合公司 美金刚口服剂型即释制剂
US20070060887A1 (en) * 2005-08-22 2007-03-15 Marsh David A Ophthalmic injector
TW200916091A (en) * 2007-06-08 2009-04-16 Merz Pharma Gmbh & Amp Co Kgaa Neramexane for the treatment of nystagmus
CN101835469A (zh) * 2007-09-12 2010-09-15 莫茨药物股份两合公司 治疗和预防听力损失的1-氨基-烷基环己烷衍生物
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
US8399519B2 (en) 2008-12-19 2013-03-19 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
CN102858321A (zh) 2010-06-18 2013-01-02 莫茨药物股份两合公司 用于局部使用1-氨基-烷基环己烷衍生物的凝胶制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (el) 1972-04-20 1973-10-23
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
EP0392059B1 (de) 1989-04-14 1993-09-15 Merz & Co. GmbH & Co. Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
ES2134804T3 (es) 1991-04-19 1999-10-16 Childrens Medical Center Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal.
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
PT1009732E (pt) 1997-06-30 2003-10-31 Merz & Co Gmbh & Co 1-amino-alquilciclo-hexanos antagonistas do receptor nmda
SE9901077D0 (sv) 1999-03-23 1999-03-23 Astra Ab Novel use
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
CA2436311A1 (en) * 2000-12-07 2002-06-13 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
AU2003251993A1 (en) * 2002-07-19 2004-02-09 Inge Grundke-Iqbal NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
CA2528622C (en) * 2003-05-27 2010-08-03 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders

Also Published As

Publication number Publication date
WO2005044228A3 (en) 2006-06-22
DK1684715T3 (da) 2011-07-11
EP2289489B1 (en) 2014-07-16
AR046314A1 (es) 2005-11-30
US20140350114A1 (en) 2014-11-27
CA2543865A1 (en) 2005-05-19
ES2362581T3 (es) 2011-07-07
US20120238631A1 (en) 2012-09-20
TW200526195A (en) 2005-08-16
SI1684715T1 (sl) 2011-07-29
ES2507500T3 (es) 2014-10-15
IL175623A (en) 2012-10-31
EP2289489A2 (en) 2011-03-02
DE602004032164D1 (de) 2011-05-19
US20070270500A1 (en) 2007-11-22
EP2289489A3 (en) 2012-06-06
PT1684715E (pt) 2011-05-02
HRP20110482T1 (hr) 2011-07-31
ATE504290T1 (de) 2011-04-15
EP1684715A2 (en) 2006-08-02
EP1684715B1 (en) 2011-04-06
AU2004287489B9 (en) 2008-10-09
CL2008000125A1 (es) 2008-03-14
PL1684715T3 (pl) 2011-09-30
TWI350750B (en) 2011-10-21
US20100035995A1 (en) 2010-02-11
WO2005044228A2 (en) 2005-05-19
AU2004287489A1 (en) 2005-05-19
AU2004287489B2 (en) 2008-08-28
CA2543865C (en) 2012-09-04
ZA200603561B (en) 2007-07-25

Similar Documents

Publication Publication Date Title
CY1111456T1 (el) Συνθεσεις περιλαμβανουσες νεραμεξανη
CY1121230T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου
CY1110419T1 (el) Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ
CY1108660T1 (el) Υγρες φαρμακευτικες τυποποιησεις παλονοσετρονης
UY31145A1 (es) Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
CY1113267T1 (el) Παραγωγα θειοφαινιου ως αγωνιστες των υποδοσεων s1p1/edg1
SE0301700D0 (sv) Novel compounds
CY1110813T1 (el) Χημικες ενωσεις
CY1122084T1 (el) Συνθεσεις που περιλαμβανουν αμλοδιπινη και μπισοπρολολη
SE0301653D0 (sv) Novel compounds
CY1108797T1 (el) Α-κρυσταλλικη μορφη του ρανελικου στροντιου, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις που την περιεχουν
GT200400146A (es) Derivados sustituidos del dioxido de tiazol-benzoisotiazol, procedimiento para su preparacion y su uso
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
NO20054945D0 (no) Orale formulering av cladribin
MX2022001161A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos.
RU2008150048A (ru) Синергетические бактерицидные композиции
WO2006133006A3 (en) 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
CY1116746T1 (el) Σταθερο ετοιμο προς χρηση ενεσιμο σκευασμα παρακεταμολης
CY1111129T1 (el) Στερεη φαρμακευτικη ενωση που περιεχει τελιθρομυκινη
EP1995249A4 (en) CAMPTOTHECIN DERIVATIVES AND USES THEREOF
TW200800993A (en) Organic compounds
CY1115815T1 (el) Υγρη μορφοποιηση toy g-csf
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
CY1106317T1 (el) Παραγωγα 1-ν-φαινυλαμινο-1η-ιμιδαζολης, ως αναστολεις αρωματασης